Psilocybin is the most-consumed plant-based psychedelic drug in the U.S., with 11.3% of individuals aged 12 or older using it in 2022. This reflects a growing societal interest.
Data supports psilocybin's efficacy and safety in treating depression, particularly in individuals who have not responded to other treatments, showcasing its potential in mental health applications.
Taking psilocybin in controlled clinical settings differs vastly from recreational use, highlighting the need for careful consideration of its legal and medical implications.
The evolving legal landscape around psychedelics leads to misconceptions about their safety; many believe decriminalization equals safety, which isn’t the case.
Collection
[
|
...
]